echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Heavy, small molecule cutting-edge Tongkang Pharmaceutical completed nearly 400 million yuan in B+ round of financing

    Heavy, small molecule cutting-edge Tongkang Pharmaceutical completed nearly 400 million yuan in B+ round of financing

    • Last Update: 2021-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Zhejiang Tongyongkang Pharmaceutical Co.
    , Ltd.
    (hereinafter referred to as "Yongkang Pharmaceutical") announced the completion of a B+ round of financing of nearly 400 million yuan.
    This round of financing was led by Guohai Innovation Capital, Haibang Fenghua and Zheshang Venture Capital Together with the investment, the old shareholders Wenzhou Investment and Changxing Financial Holdings continued to make additional investments.

    Recently, Zhejiang Tongyongkang Pharmaceutical Co.
    , Ltd.
    (hereinafter referred to as "Yongkang Pharmaceutical") announced the completion of a B+ round of financing of nearly 400 million yuan.
    This round of financing was led by Guohai Innovation Capital, Haibang Fenghua and Zheshang Venture Capital Together with the investment, the old shareholders Wenzhou Investment and Changxing Financial Holdings continued to make additional investments.

    This round of financing will be used for the 2/3 phase clinical advancement of the company's two 1.
    1-type new drug projects, the preclinical application and clinical trials of multiple international leading small molecule innovative drug projects, and the construction of innovative drug GMP preparation plants.

    This round of financing will be used for the 2/3 phase clinical advancement of the company's two 1.
    1-type new drug projects, the preclinical application and clinical trials of multiple international leading small molecule innovative drug projects, and the construction of innovative drug GMP preparation plants.

    Focus on the research and development of innovative anti-tumor drugs, based in China, and global deployment

    Focus on the research and development of innovative anti-tumor drugs, based in China, and global deployment

    Established in November 2017, TongYongkang Pharmaceutical is an innovative biomedical high-tech company based in China and facing the world.
    It has a world-class new drug R&D center.
    It has established a 6,000 square meter new drug R&D center in Zhejiang Changxing Life Science Park.
    New drug research and development centers have been established in Zhengzhou and Shanghai, and the clinical medicine department and business development department have been established in Shanghai.

    Established in November 2017, TongYongkang Pharmaceutical is an innovative biomedical high-tech company based in China and facing the world.
    It has a world-class new drug R&D center.
    It has established a 6,000 square meter new drug R&D center in Zhejiang Changxing Life Science Park.
    New drug research and development centers have been established in Zhengzhou and Shanghai, and the clinical medicine department and business development department have been established in Shanghai.



    The company focuses on the research and development of anti-tumor small molecule Best-in-class/First-in-class new drugs, and has established a high-efficiency small molecule new drug research and development platform.
    Homolog Pharma has a world-class R&D and management team, including 1 national expert, 2 Zhejiang province experts, and more than 10 overseas returnee doctoral experts.
    It has rich experience in new drug research and development of well-known multinational pharmaceutical companies and has led more than a dozen compounds into the clinical stage .
    In addition, the company has 10 clinical experts and has experience in dozens of innovative drug clinical projects.
    The team was established less than 30 months ago.
    It has completed two IND declarations for Class I new drugs and has carried out phase I clinical trials.
    Among them, the company’s core product TY9591 has been compared to Osimertinib.
    Preclinical trials and preliminary clinical results show that the product has more advantages.
    With good clinical efficacy and safety, it is expected to become the Best-in-class innovative drug of similar products.
    At the same time, TY9591 is also simultaneously developing brain metastasis indications.
    It is expected to solve the global drug-free status of brain metastasis and become the first-in-class treatment for EGFR.
    Innovative drug for mutant lung cancer brain metastasis.
    In addition, the two new target drugs independently developed by the company will submit IND applications in China/U.
    S.
    with partners in the near future, and are expected to enter the clinical phase within this year.

    Dr.
    Yusheng Wu, Chairman and CEO of Homo Health, said that Homo Health focuses on the research and development of new tumor drugs and is positioned as a pharmaceutical company with global innovation capabilities.
    He is very pleased to receive various investments including Guohai Innovation Capital.
    Highly recognized by institutions and old shareholders.
    The success of this round of financing will help the company's rapid advancement of the company's multiple pipelines of new drugs under development.
    The Tongkang team will also use faster clinical progress and a global leading pipeline to return the trust of new and existing shareholders.

    Dr.
    Yusheng Wu, Chairman and CEO of Homo Health, said that Homo Health focuses on the research and development of new tumor drugs and is positioned as a pharmaceutical company with global innovation capabilities.
    He is very pleased to receive various investments including Guohai Innovation Capital.
    Highly recognized by institutions and old shareholders.
    The success of this round of financing will help the company's rapid advancement of the company's multiple pipelines of new drugs under development.
    The Tongkang team will also use faster clinical progress and a global leading pipeline to return the trust of new and existing shareholders.

    Mr.
    Jiang En, executive director and head of the medical industry of China Sea Capital, said that TongYong Kang Pharmaceutical is an innovative drug company founded by a team with more than 20 years of research and development experience in large multinational pharmaceutical companies.
    The team has strong independent innovation and development capabilities and global resource integration.
    ability.
    The company's product pipeline focuses on the global competitive landscape and the Chinese market.
    Two major varieties have entered the clinic, and three global innovative products are about to enter the clinic.
    The product pipeline has unique positioning and leading progress, and there is great room for development.
    We continue to be optimistic about the independent research and development capabilities and resource integration capabilities of TongYongkang, and look forward to the company's rapid deployment of new global product pipelines with independent research and development as the mainstay, supplemented by resource cooperation, and soon become the world's leading innovative drug company in China.

    Mr.
    Jiang En, executive director and head of the medical industry of China Sea Capital, said that TongYong Kang Pharmaceutical is an innovative drug company founded by a team with more than 20 years of research and development experience in large multinational pharmaceutical companies.
    The team has strong independent innovation and development capabilities and global resource integration.
    ability.
    The company's product pipeline focuses on the global competitive landscape and the Chinese market.
    Two major varieties have entered the clinic, and three global innovative products are about to enter the clinic.
    The product pipeline has unique positioning and leading progress, and there is great room for development.
    We continue to be optimistic about the independent research and development capabilities and resource integration capabilities of TongYongkang, and look forward to the company's rapid deployment of new global product pipelines with independent research and development as the mainstay, supplemented by resource cooperation, and soon become the world's leading innovative drug company in China.

    Ms.
    Huang Li, a partner of Haibang Investment, said that Tongkang focuses on the development of clinically unsatisfied small molecule drugs, and its pipeline has high certainty.
    Compared with benchmark drugs, it has certain differentiated clinical advantages and will further solve the problem of drug accessibility.
    Sexual issues.
    In addition, the team has been engaged in the field of drug development for many years and has rich experience, which has laid a solid foundation for the development and promotion of the company's innovation pipeline.
    The overall pipeline layout is reasonable, and product licenses are also issued to listed companies, which also affirms the team's ability.

    Ms.
    Huang Li, a partner of Haibang Investment, said that Tongkang focuses on the development of clinically unsatisfied small molecule drugs, and its pipeline has high certainty.
    Compared with benchmark drugs, it has certain differentiated clinical advantages and will further solve the problem of drug accessibility.
    Sexual issues.
    In addition, the team has been engaged in the field of drug development for many years and has rich experience, which has laid a solid foundation for the development and promotion of the company's innovation pipeline.
    The overall pipeline layout is reasonable, and product licenses are also issued to listed companies, which also affirms the team's ability.

    Mr.
    You Xiangdong, managing partner and CEO of Zheshang Venture Capital, said that lung cancer and breast cancer are the top two tumor types in the world.
    With the continuous increase of my country's aging population, the demand for targeted drugs for these two types of diseases will gradually be released.
    At present, Tongtongkang Pharmaceutical has multiple pipelines focusing on the research and development of targeted drugs for lung cancer and breast cancer, and all of them have entered the clinical stage.
    The effectiveness, safety and R&D team of the product are all trustworthy.
    It is foreseeable that with the release of product listing requirements, the company's future listing can be expected and the potential is endless.
    We are firmly optimistic and grow together with the company.

    Mr.
    You Xiangdong, managing partner and CEO of Zheshang Venture Capital, said that lung cancer and breast cancer are the top two tumor types in the world.
    With the continuous increase of my country's aging population, the demand for targeted drugs for these two types of diseases will gradually be released.
    At present, Tongtongkang Pharmaceutical has multiple pipelines focusing on the research and development of targeted drugs for lung cancer and breast cancer, and all of them have entered the clinical stage.
    The effectiveness, safety and R&D team of the product are all trustworthy.
    It is foreseeable that with the release of product listing requirements, the company's future listing can be expected and the potential is endless.
    We are firmly optimistic and grow together with the company.

    Mr.
    Bai Guomin, Chairman of Changxing Financial Holdings, said that Homogene's innovation capability is second to none in China.
    It has developed rapidly since its launch in Changxing in 2017.
    Now it has grown into a leading small molecule oncology drug research and development company in China, and its products have been unanimous by many experts in the industry.
    Praise.
    The establishment of the GMP preparation plant in Changxing this time will greatly promote the development of Tongkang.

    Mr.
    Bai Guomin, Chairman of Changxing Financial Holdings, said that Homogene's innovation capability is second to none in China.
    It has developed rapidly since its launch in Changxing in 2017.
    Now it has grown into a leading small molecule oncology drug research and development company in China, and its products have been unanimous by many experts in the industry.
    Praise.
    The establishment of the GMP preparation plant in Changxing this time will greatly promote the development of Tongkang.

    About Guohai Innovation Capital

    About Guohai Innovation Capital

    China Sea Innovation Capital Investment Management Co.
    , Ltd.
    ("National Sea Innovation Capital") was established in January 2012.
    It is a private equity investment fund management subsidiary of securities firms approved by the China Securities Regulatory Commission with a registered capital of 2 billion yuan.
    As of the end of December 2020, the cumulative scale of assets under management exceeded 17.
    6 billion yuan, and both the scale of asset management and project exit rates were among the top in the industry.
    It has been selected as one of the top ten direct investment institutions of China's securities firms for two consecutive years, and was awarded the "Top 10 Best Private Equity Fund Subsidiaries of China's Securities Firms", "China's Top 50 Best Chinese Private Equity Investment Institutions", and "China's Best "Top 100 Private Equity Investment Institutions"; awarded as "Top 10 Best Private Equity Subsidiaries of Chinese Securities Companies" and "Top 100 Best Private Equity Investment Institutions of China" in financing China.
    Guohai Innovation Capital invests in leaders of various sub-industry around the two main lines of "technological innovation and healthy life".

    China Sea Innovation Capital Investment Management Co.
    , Ltd.
    ("National Sea Innovation Capital") was established in January 2012.
    It is a private equity investment fund management subsidiary of securities firms approved by the China Securities Regulatory Commission with a registered capital of 2 billion yuan.
    As of the end of December 2020, the cumulative scale of assets under management exceeded 17.
    6 billion yuan, and both the scale of asset management and project exit rates were among the top in the industry.
    It has been selected as one of the top ten direct investment institutions of China's securities firms for two consecutive years, and was awarded the "Top 10 Best Private Equity Fund Subsidiaries of China's Securities Firms", "China's Top 50 Best Chinese Private Equity Investment Institutions", and "China's Best "Top 100 Private Equity Investment Institutions"; awarded as "Top 10 Best Private Equity Subsidiaries of Chinese Securities Companies" and "Top 100 Best Private Equity Investment Institutions of China" in financing China.
    Guohai Innovation Capital invests in leaders of various sub-industry around the two main lines of "technological innovation and healthy life".

    About Haibang Fenghua

    About Haibang Fenghua

    Haibang Fenghua was initiated and established by Zhejiang Haibang Investment, a well-known equity investment institution in Zhejiang Province, and the entire investment management team.
    The company mainly focuses on equity investment in the early and mid-stage of life and health, digital economy and new materials.
    We adhere to the investment philosophy of "Technology + Talent", firmly believe that technology changes the world, and are committed to helping entrepreneurs with great ideals and entrepreneurial spirit.

    Haibang Fenghua was initiated and established by Zhejiang Haibang Investment, a well-known equity investment institution in Zhejiang Province, and the entire investment management team.
    The company mainly focuses on equity investment in the early and mid-stage of life and health, digital economy and new materials.
    We adhere to the investment philosophy of "Technology + Talent", firmly believe that technology changes the world, and are committed to helping entrepreneurs with great ideals and entrepreneurial spirit.

    About Zheshang Venture Capital

    About Zheshang Venture Capital

    Hangzhou Qizhen Future Innovation Fund was personally initiated by Academician Wu Zhaohui, President of Zhejiang University, and initiated and established by Zhejiang Business Venture Capital.
    The fund focuses on investing in early-stage projects, focusing on domestically-made alternative high-quality products; exploring new-generation innovative technologies; and deploying medical service terminals or platforms in specialized fields.
    50% of the proceeds of the fund will be used to donate to Zhejiang University to establish a fund for the introduction of innovative talents and medical public welfare research.

    Hangzhou Qizhen Future Innovation Fund was personally initiated by Academician Wu Zhaohui, President of Zhejiang University, and initiated and established by Zhejiang Business Venture Capital.
    The fund focuses on investing in early-stage projects, focusing on domestically-made alternative high-quality products; exploring new-generation innovative technologies; and deploying medical service terminals or platforms in specialized fields.
    50% of the proceeds of the fund will be used to donate to Zhejiang University to establish a fund for the introduction of innovative talents and medical public welfare research.

    About Wenzhou Investment

    About Wenzhou Investment

    Wenzhou Investment is a professional investment company focusing on the domestic and foreign biomedical fields.
    As a mixed-ownership professional pharmaceutical investment institution with state-owned equity participation, the main members of the company have a solid scientific research industry background and investment experience in the pharmaceutical field, and maintain good investment performance.
    Shanghai Wenzhou adheres to the concept of value investment and long-term investment, and comprehensively serves the upgrading and development of China's biomedical industry.

    Wenzhou Investment is a professional investment company focusing on the domestic and foreign biomedical fields.
    As a mixed-ownership professional pharmaceutical investment institution with state-owned equity participation, the main members of the company have a solid scientific research industry background and investment experience in the pharmaceutical field, and maintain good investment performance.
    Shanghai Wenzhou adheres to the concept of value investment and long-term investment, and comprehensively serves the upgrading and development of China's biomedical industry.

    About Changxing Financial Holdings

    About Changxing Financial Holdings

    Zhejiang Changxing Financial Holding Group Co.
    , Ltd.
    is a wholly state-owned enterprise established by the Changxing County Party Committee and Government.
    The group implements enterprise management and market operation.
    The main business is to operate and manage financial services such as fund investment, equity investment, financial leasing, factoring, and private equity management in accordance with professional and market-oriented rules, and promote the healthy and orderly development of strategic emerging industries in the region.
    The company adheres to the corporate philosophy of "integrity, stability, development, innovation, dedication, and professionalism", with a stable investment >

    Zhejiang Changxing Financial Holding Group Co.
    , Ltd.
    is a wholly state-owned enterprise established by the Changxing County Party Committee and Government.
    The group implements enterprise management and market operation.
    The main business is to operate and manage financial services such as fund investment, equity investment, financial leasing, factoring, and private equity management in accordance with professional and market-oriented rules, and promote the healthy and orderly development of strategic emerging industries in the region.
    The company adheres to the corporate philosophy of "integrity, stability, development, innovation, dedication, and professionalism", with a stable investment >
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.